Home > Press > Tegal Corporation Reports Fiscal 2008 Net Income of $2.48 Per Diluted Share and $2.18 for the Fourth Quarter
Abstract:
Tegal Corporation (NASDAQ: TGAL), a leading designer and manufacturer of plasma etch and deposition systems used in the production of integrated circuits and nanotechnology devices, today announced financial results for the fourth quarter and fiscal year 2008, which ended March 31, 2008. Senior management will conduct an investor conference call to discuss these results and the Company's financial outlook in more detail today, June 16, 2008 at 2:00pm PDT. More information about the conference call is provided below.
Fiscal 2008 Highlights
-- Fiscal year 2008 revenues were $32.9 million, an increase of 47.9% over the prior fiscal year. Gross margins were 42.6%, compared to 24.8% in the prior year. Operating income for fiscal 2008 was $1.6 million and net income was $18.1 million or $2.48 per diluted share. Fourth quarter net income included other income of $15.0 million, resulting primarily from the final settlement of a fee dispute with the Company's attorneys.
-- The Company's cash balance at the end of the fiscal year was $19.3 million, compared to $25.8 million at the end of fiscal 2007, and $19.8 million at the end of the third quarter of fiscal 2008.
-- In March 2008, the Company signed a distributor agreement with WESI Technology (China), a joint-venture between WKK and ECI Technology, Inc., for the sales, service and technical support of its products in China and Taiwan.
-- Following fiscal year end, the Company announced a Beta site agreement with a leading High-Brightness LED manufacturer which will include the shipment of a Compact 360 NLD system early in the second quarter of fiscal 2009.
"Fiscal 2008 was the culmination of a successful three-year effort to turn our Company around. I want to thank our shareholders for their support and personally thank our employees whose hard work and perseverance made all of the difference," said Thomas Mika, Chairman, President and CEO of Tegal Corporation. "We were fortunate this year to be able to overcome a strong headwind in the semiconductor capital equipment market, due largely to our focus on faster growth, non-mainstream device markets. Compared to many of our competitors, including companies much larger than Tegal, we are in an enviable position of having a relatively strong balance sheet, a lean organization, and the needed flexibility to prosper in a challenging environment."
Financial Results
Fourth quarter revenues were $7.4 million, up 19.5% from $6.2 million in the same period of the prior year. Revenues for fiscal 2008 were $32.9 million, compared to $22.3 million in the prior fiscal year - an increase of 47.9%.
Fourth quarter gross margins were 50.6%, compared to 31.5% in the same quarter one year ago. Fiscal 2008 gross margins were 42.6%, compared to 24.8% in 2007.
Operating income for the fourth quarter was $0.8 million, compared to a loss of ($2.0) million in the same quarter one year ago. The Company's operating income for the full year was $1.6 million, compared to an operating loss of ($13.4) million in fiscal 2007. Operating expenses during the fiscal year included approximately $1.6 million for non-cash charges for depreciation, amortization, and stock compensation expense.
Tegal reported a net income of $15.2 million, or $2.18 per diluted share, for the quarter, compared to a net loss of ($2.0) million, or ($0.28) per share in the comparable quarter one year ago.
Cash at the end of the fiscal fourth quarter of 2008 was $19.3 million, down $6.5 million from the same quarter one year ago.
Investor Conference Call
The company will host a conference call for investors today (Monday, June 16) at 5:00 p.m. EDT / 2:00 p.m. PDT. The dial-in phone numbers are 800/901-5218 or 617/786-4511. Investors should reference passcode 53323889. A digital recording will be made available two hours after the completion of the conference call, and it will be accessible through midnight on Monday, June 23, 2008. To access, investors should dial 888/286-8010 or 617/801-6888 and enter passcode: 25258540. The conference call also will be available live via the Investor Section of the Company's website at: www.tegal.com. A replay of the teleconference, along with a copy of the Company's earnings release, will be available on the Company's website, as well.
Safe Harbor Statement
Except for historical information, matters discussed in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements, which are based on assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words "anticipate," "believe," "estimate," "expect," "intend," "project" or similar expressions. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company including, but not limited to industry conditions, economic conditions, acceptance of new technologies and market acceptance of the Company's products and services. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph. For a further discussion of these risks and uncertainties, please refer to the Company's periodic filings with the Securities and Exchange Commission.
####
About Tegal Corporation
Tegal provides process and equipment solutions to leading edge suppliers of advanced semiconductor and nanotechnology devices. Incorporating unique, patented etch and deposition technologies, Tegal's system solutions are backed by over 35 years of advanced development and over 100 patents. Some examples of devices enabled by Tegal technology are energy efficient memories found in portable computers, cell phones, PDAs and RFID applications; megapixel imaging chips used in digital and cell phone cameras; power amplifiers for portable handsets and wireless networking gear; and MEMS devices like accelerometers for automotive airbags, microfluidic control devices for ink jet printers; and laboratory-on-a-chip medical test kits.
TEGAL CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands) ASSETS March 31, March 31, 2008 2007 ---------- ---------- Current assets: Cash and cash equivalents $ 19,271 $ 25,776 Trade receivables, net 6,758 6,634 Inventories 11,056 5,567 Prepaid expenses and other current assets 788 991 ---------- ---------- Total current assets 37,873 38,968 Property and equipment, net 1,213 1,351 Intangible assets, net 903 1,161 Other assets 90 176 ---------- ---------- Total assets $ 40,079 $ 41,656 ========== ========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Notes payable $ 14 $ 10 Accounts payable 1,469 1,974 Product warranty 1,770 1,101 Accrued expenses and other current liabilities 3,644 3,590 Litigation Suspense - 19,500 Deferred revenue 252 1,064 ---------- ---------- Total liabilities 7,149 27,239 ---------- ---------- Stockholders' equity: Common stock 72 71 Additional paid-in capital 123,567 122,473 Accumulated other comprehensive income (446) 240 Accumulated deficit (90,263) (108,367) ---------- ---------- Total stockholders' equity 32,930 14,417 ---------- ---------- $ 40,079 $ 41,656 ========== ========== TEGAL CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended Twelve Months Ended March 31, March 31, ------------------ ------------------- 2008 2007 2008 2007 -------- --------- -------- ---------- Revenue $ 7,382 $ 6,197 $ 32,925 $ 22,263 Cost of revenue 3,649 4,242 18,911 16,736 -------- --------- -------- ---------- Gross profit (loss) 3,733 1,955 14,014 5,527 -------- --------- -------- ---------- Operating expenses: Research and development 1,060 1,507 3,705 4,646 Sales and marketing 955 952 4,163 3,909 General and administrative 962 1,497 4,551 10,347 Total operating expenses 2,977 3,956 12,419 18,902 -------- --------- -------- ---------- Operating income (loss) 756 (2,001) 1,595 (13,375) Other income (expense) 14,959 (4) 17,013 162 -------- --------- -------- ---------- Net income (loss) before taxes 15,715 (2,005) 18,608 (13,213) Income taxes 500 - 504 - Net income (loss) after taxes $ 15,215 $ (2,005) $ 18,104 $ (13,213) ======== ========= ======== ========== Net income (loss) per share, basic $ 2.19 $ (0.28) $ 2.53 $ (1.87) ======== ========= ======== ========== Net income (loss) per share, diluted $ 2.18 $ (0.28) $ 2.48 $ (1.87) ======== ========= ======== ========== Shares used in per share computation: Basic 7,172 7,107 7,159 7,065 Diluted 7,196 7,107 7,288 7,065
For more information, please click here
Contacts:
Tegal Corporation
Christine Hergenrother, 707/763-5600
(Vice President & CFO)
or
The Blueshirt Group
Gina DeBoutez, 415/217-7722
Chris Danne, 415/217-7722
Copyright © Business Wire 2008
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Chip Technology
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Groundbreaking precision in single-molecule optoelectronics August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Tools
Turning up the signal November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||